Few things are more frustrating than finally finding a hormone therapy routine that gives you your sleep, your mood, and your energy back, only to be told at the pharmacy that your patch is unavailable. In my practice here in New Jersey, this has become one of the most common calls we get. Women are rationing patches, driving from pharmacy to pharmacy, and sometimes simply going without.
I want to give you a calm, practical plan. Please treat everything below as a guide for conversations with your pharmacist and your clinician, not as instructions to change your treatment yourself. Any change in dose, product, or route requires a new prescription from someone who knows your history.
The practical takeaway is simple: availability depends on the manufacturer, the strength, the schedule, and the pharmacy, and it changes week to week.
What Is Actually Going On
In late 2025, the FDA announced it would remove the long-standing boxed warnings about breast cancer, cardiovascular disease, and dementia from menopausal hormone therapy labeling, and updated labels followed in early 2026. Many more women became willing to consider treatment, and many more clinicians became comfortable prescribing it. Demand rose quickly.
Transdermal patches are not simple to make. They require specialized equipment and manufacturing lines, and scaling up takes time. In its September 2026 update, the FDA said it is working with all six manufacturers of estradiol patches, that supply has nearly doubled over the past year, and that patches "remain available," although specific brands and strengths vary by pharmacy and location. The FDA has not placed estradiol patches on its official shortage list.
The American Society of Health-System Pharmacists, which tracks shortages based on reports from pharmacists and providers, has listed estradiol transdermal systems as a shortage since January 2026. The two organizations use different definitions, which is why you may hear conflicting messages. In October, several U.S. senators wrote to the FDA asking what it would take to declare an official shortage, which could unlock additional tools to increase supply.
The practical takeaway is simple: availability depends on the manufacturer, the strength, the schedule, and the pharmacy, and it changes week to week. That is actually good news, because it means there is often a version of your patch somewhere.
First, the Non-Negotiables
Before we talk about options, three rules.
Do not stop treatment because you ran out. Stopping suddenly can bring hot flashes, night sweats, sleep disruption, and mood changes back quickly. If your supply is running low and you cannot reach a solution, call your clinician's office and say clearly, "I am about to run out of my estrogen." That is a clinical problem, and it deserves a clinical answer.
Do not stretch, cut, or double up patches without guidance. Wearing a patch longer than directed, cutting patches, or stacking extras to make your supply last can deliver unpredictable doses.
Never pause your progestogen. If you have a uterus, your progesterone or progestin protects the lining of your uterus from the effects of estrogen. That protection must continue without interruption through any change in your estrogen. This is the single most important safety point in this article.
Step One: Try to Stay on a Patch
For most women, the best first move is not a new medication. It is the same medication from a different source.
A different manufacturer. Several companies make estradiol patches, and the shortage has been uneven across them. Your pharmacist can often fill your prescription with an equivalent patch of the same strength and schedule from a manufacturer that has stock. In New Jersey, as in most states, pharmacists can generally substitute an equivalent generic unless your prescriber has indicated otherwise, but ask whether your prescription is written in a way that allows it.
A different schedule or strength. Patches come in twice-weekly and once-weekly versions. If one is unavailable, the other may be in stock. Sometimes your clinician can also prescribe a combination of patch strengths to reach your usual dose. These changes do require a new prescription.
A different pharmacy. Independent pharmacies, other locations in your chain, mail-order pharmacies, and 90-day fills can all help. Ask your pharmacy to transfer your prescription if you find stock elsewhere; many will not suggest it unless you ask.
Refill early. Request your refill as soon as your insurance allows, ideally a couple of weeks before your last patch. That buffer gives you time to solve problems before you are out.
Here are the questions I suggest bringing to the pharmacy counter:
Can you fill this with another manufacturer's patch at the same strength and schedule?
If my twice-weekly patch is out, do you have the once-weekly version, or the reverse?
Which strengths do you have in stock right now, so my clinician can work with them?
Can you check your other locations or your mail-order service?
If nothing works, will you call my clinician directly with what you do have?
That last question is powerful. A five-minute call between pharmacist and prescriber often solves what would otherwise take days of back and forth.
Step Two: If You Need to Switch, Know Your Options
If no patch is available, there are other good ways to receive estrogen. They are not identical, so this is a conversation for your clinician.
Gels and sprays. These are absorbed through the skin, just like a patch, so they are usually the closest match. Options include estradiol gels in pumps or single-dose packets and an estradiol forearm spray. They require daily application and a little attention to where you apply them and who touches that skin afterward.
A systemic vaginal ring. Femring releases estrogen into the whole body for three months at a time. It is different from the low-dose vaginal rings, creams, and inserts that treat only local vaginal and bladder symptoms. Those local products are excellent for genitourinary symptoms but are not a replacement for a systemic patch.
Oral estradiol. For many healthy women, a tablet is a reasonable temporary or long-term substitute. For some women, it is not the right choice, which brings us to route.
Combination products. If you are switching anyway, products that combine estrogen with a progestogen in one pill can simplify things. One combination patch exists as well, but because it is also a patch, it may be affected by the same supply problems.
A word about compounded hormones: compounded estradiol creams are not FDA-approved, and their strength and consistency can vary. The Menopause Society recommends FDA-approved products whenever they are available. Ask your clinician about approved options first.
Why Route Matters
Estrogen you swallow passes through the liver before reaching the rest of your body. That "first pass" changes how the liver makes clotting factors, triglycerides, and other proteins. Estrogen absorbed through the skin largely bypasses this step. Large studies have found that oral estrogen is associated with a higher risk of blood clots, while transdermal estrogen at standard doses has not shown the same increase.
For that reason, transdermal delivery is generally preferred if you have a history of or higher risk for blood clots, migraine with aura, elevated triglycerides, gallbladder disease, a higher body weight, or certain cardiovascular risk factors. If any of these apply to you, ask specifically whether a gel or spray can keep you on the transdermal route before moving to a pill.
A Rough Guide to Equivalent Doses
Your clinician will choose your new dose, but it helps to understand that there is a shared reference point. The Canadian Menopause Society publishes a consensus equivalency table that many clinicians use. In approximate terms:
Low dose: a 25 mcg patch is roughly comparable to 0.5 mg of oral estradiol, one pump of EstroGel, or a 0.5 mg Divigel packet
Standard dose: a 50 mcg patch is roughly comparable to 1 mg of oral estradiol, one to two pumps of EstroGel, or a 1 mg Divigel packet
Higher doses are generally reserved for women with premature ovarian insufficiency or surgical menopause
These are approximations, not exact conversions. Absorption varies between products and between women, so your clinician may adjust your dose over the following weeks based on how you feel. Some products, including Femring, Elestrin gel, and the forearm spray, are dosed by response rather than by chart. And be cautious with ultra-low-dose products: if that is all your pharmacy has, it is a different, lower treatment, not a smaller version of your current one.
Your Progestogen Plan Stays in Place
If you have a uterus, your progestogen continues through every step of this process. Its dose is matched to your estrogen dose, so if your estrogen dose goes up with a switch, your progestogen may need to be adjusted too. Call your clinician if you develop unexpected bleeding after a change. Some women use a levonorgestrel IUD for uterine protection; it is widely used for this purpose, though it is considered off-label in the United States.
Questions to Bring to Your Clinician
Can I stay on a patch through a different manufacturer, schedule, or strength?
If I switch, what dose is equivalent to what I take now?
Does anything in my history make oral estrogen a poorer choice for me?
Does my progestogen need to change?
How long should I give a new product before deciding it is not working?
Which symptoms should prompt a call to the office?
What is the plan for switching back when my patch is available again?
Make Your Experience Count
Official shortage decisions depend partly on reports from patients and clinicians. If you cannot fill your prescription, you can report it to the FDA's Drug Shortage Staff at drugshortages@fda.hhs.gov, and you can contact the manufacturer of your patch with your product, dose, ZIP code, and how many times your prescription went unfilled. If a patch caused a side effect or did not stick, that is a separate safety report, which you can file through the manufacturer or the FDA's MedWatch program.
You fought hard to feel like yourself again. A supply problem should not take that away. Advocate for yourself with your pharmacist, your clinician, and your representatives, and if your provider is not willing to work through the options with you, find one who will.
Defy Menopause - Own the Change
Many women tell me: "One day I feel amazing. The next, I can barely get out of bed. Is this normal?"
Yes, it is. And no, you don’t have to suffer through it alone.
Hormonal fluctuations during perimenopause can make you feel like you’ve lost control of your body. But knowledge is powerful. And there are clear, science-backed ways to support your hormones, ease symptoms, and reclaim your energy.
That’s exactly why I created Defy Menopause: Own the Change — a 30-day program designed to give you the tools, knowledge, and support you need to move through these changes with clarity and confidence.
Inside, you’ll find:
Access to Dr. Tracy Verrico at one (1) live, group session
Clear action steps for managing symptoms naturally
Because you deserve more than just "putting up with it."
You deserve to thrive.
Let’s Connect
Schedule an Appointment | LinkedIn | YouTube | Instagram | Bona Dea Gynecology
Medical Disclaimer: The information provided in this blog is for general educational and informational purposes only and is not intended as, nor should it be considered, medical advice. This content does not establish a physician-patient relationship and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read in this newsletter. If you think you may have a medical emergency, call your doctor or emergency services immediately.
References
U.S. Food and Drug Administration. FDA Update on Estradiol Transdermal Patch Availability. September 3, 2026.
U.S. Food and Drug Administration. FDA Approves Labeling Changes to Menopausal Hormone Therapy Products. February 12, 2026.
U.S. Department of Health and Human Services. HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy. November 10, 2025.
American Society of Health-System Pharmacists. Drug Shortages: Estradiol Transdermal System. Bulletin created January 30, 2026.
Office of U.S. Senator Kirsten Gillibrand. Gillibrand, Duckworth, Schiff Press FDA On Plan To Mitigate Estrogen Patch Shortage. October 21, 2026.
The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.
Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019;364:k4810.
Canadian Menopause Society. Systemic Menopause Hormone Therapy Equivalency Table.
The Menopause Society. Compounded Bioidentical Hormone Therapy: position and consumer guidance.
